Atypical hemolytic uremic syndrome (aHUS) is a rare, genetic, life-threatening disease. The Global aHUS Registry collects real-world data on the natural history of the disease. Here we characterize end-stage renal disease (ESRD)-free survival, the rate of thrombotic microangiopathy, organ involvement and the genetic background of 851 patients in the registry, prior to eculizumab treatment. A sex-specific difference was apparent according to age at initial disease onset as the ratio of males to females was 1.3:1 for childhood presentation and 1:2 for adult presentation. Complement Factor I and Membrane Cofactor Protein mutations were more common in patients with initial presentation as adults and children, respectively. Initial presentation in childhood significantly predicted ESRD risk (adjusted hazard ratio 0.55 [95% confidence interval 0.41–0.73], whereas sex, race, family history of aHUS, and time from initial presentation to diagnosis, did not. Patients with a Complement Factor H mutation had reduced ESRD-free survival, whereas Membrane Cofactor Protein mutation was associated with longer ESRD-free survival. Additionally extrarenal organ manifestations occur in 19%–38% of patients within six months of initial disease presentation (dependent on organ). Thus, our real-world results provide novel insights regarding phenotypic variables and genotypes on the clinical manifestation and progression of aHUS.

Original languageEnglish
Pages (from-to)408-418
Number of pages11
JournalKidney International
Issue number2
StatePublished - Aug 2018


FundersFunder number
Quintiles company290 2005 00351 TO7
Alexion Pharmaceuticals
Medical Research CouncilG0800671


    • complement
    • hemolytic uremic syndrome
    • thrombotic microangiopathy


    Dive into the research topics of 'Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome'. Together they form a unique fingerprint.

    Cite this